Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases

ALS News Today
|
October 8, 2020
X min read
ALS News Today
|
October 8, 2020
Share on Social
share on Twitter or X
share on Linkedin
share onFacebook
share on Bluesky

More like this

News

Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference

March 7, 2025

Read Now
Press

Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference

March 7, 2025

Read Now
News

Scribe Therapeutics to Participate in Upcoming Conferences

February 26, 2025

Read Now
Press

Scribe Therapeutics to Participate in Upcoming Conferences

February 26, 2025

Read Now
News

Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi

January 13, 2025

Read Now
Press

Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi

January 13, 2025

Read Now
See More